Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13.65	19.76	23.63	17.11	38.99	18.27
Short-Term Investments	15.72	15.07	20.93	5.07	-	20.28
Cash & Short-Term Investments	29.37	34.83	44.56	22.18	38.99	38.55
Cash Growth	7.16%	-21.84%	100.90%	-43.11%	1.14%	116.64%
Accounts Receivable	14.43	2.91	5.27	4.59	3.44	2
Other Receivables	-	0.49	0.48	0.36	0.31	0.77
Receivables	14.43	3.4	5.75	4.95	3.75	2.77
Inventory	21.26	21.24	19.05	16.8	17.95	13.08
Prepaid Expenses	-	0.5	0.44	0.77	0.91	0.84
Other Current Assets	1.45	0.11	0.13	0.17	0.07	0.48
Total Current Assets	66.5	60.08	69.93	44.88	61.67	55.72
Property, Plant & Equipment	12.53	10.02	10.88	9.64	9.92	10.41
Long-Term Deferred Tax Assets	2.68	2.86	3.09	-	-	-
Other Long-Term Assets	0.55	0.46	0.53	1.27	2.08	1.8
Total Assets	82.26	73.42	84.43	55.79	73.67	67.93
Accounts Payable	5.38	4.53	4.32	5.86	6.99	7.22
Accrued Expenses	11.64	13.8	13.2	11.6	16.34	13.61
Current Portion of Long-Term Debt	-	-	20.25	-	-	58.51
Current Portion of Leases	1.4	1.5	1.41	1.12	1.21	1.42
Current Income Taxes Payable	2.39	3.48	2.88	0.53	-	-
Current Unearned Revenue	-	-	-	13.18	8.55	5.39
Other Current Liabilities	1.15	2.31	3.48	0.14	0.1	0.32
Total Current Liabilities	21.95	25.62	45.53	32.43	33.18	86.47
Long-Term Debt	-	-	-	28.19	27.89	-
Long-Term Leases	6.78	4.03	4.62	4.17	4.38	4.47
Long-Term Unearned Revenue	-	-	-	-	11.79	1.72
Pension & Post-Retirement Benefits	0.63	0.56	0.71	1.64	2.47	2.26
Other Long-Term Liabilities	-	-	-	-	-	0.05
Total Liabilities	29.36	30.21	50.87	66.43	79.7	94.97
Common Stock	0.08	0.08	0.07	0.05	0.05	0.04
Additional Paid-In Capital	432.32	421.53	415.05	379.17	368.85	320.28
Retained Earnings	-379.49	-378.39	-381.55	-389.86	-374.93	-347.35
Shareholders' Equity	52.91	43.21	33.57	-10.64	-6.04	-27.04
Total Liabilities & Equity	82.26	73.42	84.43	55.79	73.67	67.93
Total Debt	8.18	5.53	26.28	33.47	33.47	64.4
Net Cash (Debt)	21.19	29.3	18.28	-11.29	5.52	-25.86
Net Cash Growth	-2.45%	60.31%	-	-	-	-
Net Cash Per Share	0.25	0.36	0.22	-0.23	0.12	-0.89
Filing Date Shares Outstanding	80.42	78.03	73.05	57.35	46.32	45.38
Total Common Shares Outstanding	80.34	75.85	72.95	53.79	45.56	34.77
Working Capital	44.56	34.46	24.4	12.45	28.49	-30.75
Book Value Per Share	0.66	0.57	0.46	-0.20	-0.13	-0.78
Tangible Book Value	52.91	43.21	33.57	-10.64	-6.04	-27.04
Tangible Book Value Per Share	0.66	0.57	0.46	-0.20	-0.13	-0.78
Machinery	-	22.42	22.02	21.32	20.96	20.11
Leasehold Improvements	-	17.91	17.64	16.92	16.76	16.66

Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q